AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37769428 — intervention group
Group type: EXPERIMENTAL
Intervention: Inebilizumab
Number of subjects: 47
Study 37769428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 37769429 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA vaccine (2 or 3 doses after ≥1 month of subcutaneous ofatumumab 20 mg/month)
Number of subjects: 26
Study 37769429 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA vaccine (3 doses)
Number of subjects: 26
Study 37769429 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA vaccine (2 doses)
Number of subjects: 26
Study 37769429 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA vaccine (for patients aged <40 years without previous anti-CD20 therapy)
Number of subjects: 26
Study 37769545 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM)
Number of subjects: 287
Study 37769545 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release carbamazepine (CBZ-CR)
Number of subjects: 287
Study 37769610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiologists interpreting SL-ECGs
Number of subjects: 450
Study 37769610 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal medicine residents interpreting SL-ECGs
Number of subjects: 450
Study 37769610 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical students (years 4-6) interpreting SL-ECGs
Number of subjects: 450
Study 37769610 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical students (years 1-3) interpreting SL-ECGs
Number of subjects: 450
Study 37769610 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with prior experience interpreting SL-ECGs
Number of subjects: 450
Study 37769610 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with no prior experience interpreting SL-ECGs
Number of subjects: 450
Study 37769610 — intervention group
Group type: EXPERIMENTAL
Intervention: First five interpreted SL-ECGs
Number of subjects: 450
Study 37769610 — intervention group
Group type: EXPERIMENTAL
Intervention: Last five interpreted SL-ECGs
Number of subjects: 450
Study 37769610 — intervention group
Group type: COMPARATOR
Intervention: Comparison of accuracy between five smart devices
Number of subjects: 450
Study 37769610 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple Watch SL-ECGs
Number of subjects: 450
Study 37769619 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad hoc CTO PCI
Number of subjects: 899
Study 37769619 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-ad hoc CTO PCI)
Number of subjects: 899
Study 37770111 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37770120 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal sufentanil
Number of subjects: 170
Study 37770120 — intervention group
Group type: COMPARATOR
Intervention: Oral/intravenous opioids
Number of subjects: 170
Study 37770132 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive therapies (silver diamine fluoride, self-assembling peptide P)
Number of subjects: 1000
Study 37770132 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive therapies (including self-assembling peptide P)
Number of subjects: 1000
Study 37770132 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical scenarios with noninvasive therapies
Number of subjects: 1000
Study 37770186 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow wave sleep (SWS)
Number of subjects: 135
Study 37770186 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reserve (CR) proxies
Number of subjects: 135
Study 37770186 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cognitive reserve (CR)
Number of subjects: 135
Study 37770267 — intervention group
Group type: EXPERIMENTAL
Intervention: SEARCH algorithm for post-PE diagnoses
Number of subjects: 150
Study 37770273 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatectomy combined with apatinib and camrelizumab
Number of subjects: 0
Study 37770278 — intervention group
Group type: EXPERIMENTAL
Intervention: Short screening for CRF using five items at high frequency during therapy and lower frequency during post-treatment phase for 18 months
Number of subjects: 300
Study 37770278 — intervention group
Group type: EXPERIMENTAL
Intervention: Online assessments of psychological, socio-demographical, or medical factors that may exacerbate CRF
Number of subjects: 300
Study 37770277 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC)
Number of subjects: 46
Study 37770277 — intervention group
Group type: COMPARATOR
Intervention: Sham conditioning
Number of subjects: 46
Study 37770309 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release/extended-release methylphenidate (DR/ER-MPH)
Number of subjects: 395
Study 37770476 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep duration (≤5h)
Number of subjects: 445966
Study 37770476 — intervention group
Group type: EXPERIMENTAL
Intervention: Long sleep duration (≥10h)
Number of subjects: 445966
Study 37770476 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP-based heritability for both sleep traits
Number of subjects: 445966
Study 37770476 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic correlation between short and long sleep traits
Number of subjects: 445966
Study 37770652 — intervention group
Group type: EXPERIMENTAL
Intervention: Garetosmab (activin A-blocking antibody)
Number of subjects: 44
Study 37770652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 37770704 — intervention group
Group type: EXPERIMENTAL
Intervention: High-FN-risk chemotherapy regimen
Number of subjects: 3605
Study 37770704 — intervention group
Group type: COMPARATOR
Intervention: Low and intermediate FN-risk chemotherapy regimens
Number of subjects: 3605
Study 37770748 — intervention group
Group type: EXPERIMENTAL
Intervention: Different surgical approaches for total mesorectal excision (TME)
Number of subjects: 0
Study 37770770 — intervention group
Group type: EXPERIMENTAL
Intervention: SPC R10/E10
Number of subjects: 305
Study 37770770 — intervention group
Group type: COMPARATOR
Intervention: R10
Number of subjects: 305
Study 37770865 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ppm hypochlorous acid mouthwash (MW)
Number of subjects: 83
Study 37770865 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ppm hypochlorous acid mouthwash with periodontal flosser (MWPF)
Number of subjects: 83
Study 37770865 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 83
Study 37770881 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-body and Art Therapies (MBATs)
Number of subjects: 150
Study 37770881 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-list)
Number of subjects: 150
Study 37770889 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab treatment
Number of subjects: 204
Study 37770908 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum (8-10 mmHg)
Number of subjects: 100
Study 37770908 — intervention group
Group type: COMPARATOR
Intervention: Standard-pressure pneumoperitoneum (12-14 mmHg)
Number of subjects: 100
Study 37770908 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure laparoscopic cholecystectomy
Number of subjects: 100
Study 37770908 — intervention group
Group type: COMPARATOR
Intervention: Standard-pressure laparoscopic cholecystectomy
Number of subjects: 100
Study 37770944 — intervention group
Group type: EXPERIMENTAL
Intervention: VISA-G-Norwegian questionnaire
Number of subjects: 78
Study 37770944 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest reliability
Number of subjects: 78
Study 37770944 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Difference Change (SDC)
Number of subjects: 78
Study 37770967 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Dialogue (HD)
Number of subjects: 64
Study 37771274 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 6263
Study 37771274 — intervention group
Group type: COMPARATOR
Intervention: COVID-19
Number of subjects: 6263
Study 37771274 — intervention group
Group type: COMPARATOR
Intervention: No COVID-19
Number of subjects: 6263
Study 37771274 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 survivors
Number of subjects: 6263
Study 37771545 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir-pibrentasvir 300 mg-120 mg daily for 4 weeks
Number of subjects: 23
Study 37771546 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Number of subjects: 1632
Study 37771546 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 1632
Study 37771697 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth model for preanesthesia evaluation
Number of subjects: 25
Study 37771697 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in videoconferencing
Number of subjects: 25
Study 37771697 — intervention group
Group type: EXPERIMENTAL
Intervention: Themes identified from interviews
Number of subjects: 25
Study 37772038 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of biomarkers of physical activity and health
Number of subjects: 180
Study 37772038 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions aimed to improve quality of life through physical activity
Number of subjects: 180
Study 37772064 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37772075 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0
Study 37772075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37772282 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine (6-48 mg daily)
Number of subjects: 228
Study 37772419 — intervention group
Group type: EXPERIMENTAL
Intervention: CTCA + ICA
Number of subjects: 688
Study 37772419 — intervention group
Group type: COMPARATOR
Intervention: ICA alone
Number of subjects: 688
Study 37772436 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06817024 (10-1000 mg single intravenous doses)
Number of subjects: 0
Study 37772436 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06817024 (single dose)
Number of subjects: 0
Study 37772436 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06817024 (repeat doses)
Number of subjects: 0
Study 37772436 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06817024 (single intravenous administration)
Number of subjects: 0
Study 37772436 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06817024
Number of subjects: 0
Study 37772607 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 0
Study 37772607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37772663 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic full-field optical coherence tomography (D-FFOCT)
Number of subjects: 152
Study 37772663 — intervention group
Group type: COMPARATOR
Intervention: Conventional processing and staining (hematoxylin-eosin)
Number of subjects: 152
Study 37772721 — intervention group
Group type: EXPERIMENTAL
Intervention: TA-NRP Heart DCD
Number of subjects: 219
Study 37772721 — intervention group
Group type: COMPARATOR
Intervention: SRR Super Rapid Recovery DCD
Number of subjects: 219
Study 37772721 — intervention group
Group type: COMPARATOR
Intervention: Super Rapid Recovery non-heart DCD
Number of subjects: 219
Study 37772721 — intervention group
Group type: COMPARATOR
Intervention: Donations after brain death
Number of subjects: 219
Study 37772762 — intervention group
Group type: EXPERIMENTAL
Intervention: E6742, a specific antagonist of toll-like receptors 7/8
Number of subjects: 0
Study 37772762 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37772853 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial microscopy evaluation of sputum samples
Number of subjects: 0
Study 37772853 — intervention group
Group type: COMPARATOR
Intervention: BioFire FilmArray Pneumonia Panel
Number of subjects: 0
Study 37772889 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-glucose transporter 2 inhibitors and sparsentan as part of supportive care in patients with chronic kidney damage.
Number of subjects: 0
Study 37772889 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic glucocorticoids in high-risk patients.
Number of subjects: 0
Study 37772889 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted-release budesonide, anti-B-cell strategies, and selective complement inhibition.
Number of subjects: 0
Study 37772889 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical parameters including degree of proteinuria, presence of persistent microscopic hematuria, rate of eGFR loss, mesangial hypercellularity, endocapillary hypercellularity, segmental glomerulosclerosis, tubular atrophy/interstitial fibrosis, crescents score.
Number of subjects: 0
Study 37772984 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care intervention
Number of subjects: 286
Study 37772984 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 286
Study 37773052 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccination in PWWH
Number of subjects: 227
Study 37773052 — intervention group
Group type: COMPARATOR
Intervention: Tdap vaccination in HIV-uninfected women
Number of subjects: 227
Study 37773052 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccination in both groups
Number of subjects: 227
Study 37773067 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-h sepsis bundle initiation
Number of subjects: 18
Study 37773067 — intervention group
Group type: COMPARATOR
Intervention: 3-h sepsis bundle initiation
Number of subjects: 18
Study 37773067 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategy for both 1-h and 3-h bundles
Number of subjects: 18
Study 37773184 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent COVID-19 vaccines
Number of subjects: 252
Study 37773189 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 0
Study 37773189 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 0
Study 37773189 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 0
Study 37773189 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID vs 10 mg BID
Number of subjects: 0
Study 37773189 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate vs Tofacitinib
Number of subjects: 0
Study 37773297 — intervention group
Group type: EXPERIMENTAL
Intervention: Active production of music
Number of subjects: 300
Study 37773297 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 300
Study 37773418 — intervention group
Group type: EXPERIMENTAL
Intervention: One repeated subgingival instrumentation (RSI)
Number of subjects: 25
Study 37773418 — intervention group
Group type: EXPERIMENTAL
Intervention: Two repeated subgingival instrumentations (RSI)
Number of subjects: 25
Study 37773479 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell transplantation (MSCT)
Number of subjects: 23
Study 37773479 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultivated limbal epithelial transplantation (CLET)
Number of subjects: 23
Study 37773479 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCT
Number of subjects: 23
Study 37773479 — intervention group
Group type: EXPERIMENTAL
Intervention: CLET
Number of subjects: 23
Study 37773479 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCT and CLET
Number of subjects: 23
Study 37773497 — intervention group
Group type: EXPERIMENTAL
Intervention: High-cash gift ($333/mo, or $3996/y)
Number of subjects: 1000
Study 37773497 — intervention group
Group type: COMPARATOR
Intervention: Low-cash gift ($20/mo, or $240/y)
Number of subjects: 1000
Study 37773498 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth diabetes intervention (remote support from clinical pharmacists via video telehealth, health coach activities in person and via phone/text)
Number of subjects: 221
Study 37773498 — intervention group
Group type: COMPARATOR
Intervention: waiting list control group (usual diabetes care for 1 year)
Number of subjects: 221
Study 37773498 — intervention group
Group type: COMPARATOR
Intervention: waiting list control group (received mHealth intervention after 1 year)
Number of subjects: 221
Study 37773498 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth diabetes intervention (continued for intervention group)
Number of subjects: 221
Study 37773600 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (rehabilitation)
Number of subjects: 69
Study 37773606 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-factor model of the Maladaptive Personality and Interpersonal Schema (MPIS)
Number of subjects: 234
Study 37773606 — intervention group
Group type: EXPERIMENTAL
Intervention: MPIS questionnaire
Number of subjects: 234
Study 37773616 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital PrEP navigation and activation intervention (PrEPresent)
Number of subjects: 150
Study 37773618 — intervention group
Group type: EXPERIMENTAL
Intervention: Supporting Transitions to Adulthood and Reducing Suicide (STARS) alongside Safety Planning Intervention (SPI)
Number of subjects: 60
Study 37773618 — intervention group
Group type: COMPARATOR
Intervention: Safety Planning Intervention (SPI) alone
Number of subjects: 60
Study 37773624 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app intervention (IG)
Number of subjects: 70
Study 37773624 — intervention group
Group type: COMPARATOR
Intervention: Routine preparations (CG)
Number of subjects: 70
Study 37773627 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 37773633 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic ascorbate (P-AscH-) combined with radiation and temozolomide
Number of subjects: 55
Study 37773633 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic ascorbate (P-AscH-)
Number of subjects: 55
Study 37774014 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19 CAR T-cell therapy
Number of subjects: 47
Study 37774185 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2mg/kg with saline infusion (GL)
Number of subjects: 60
Study 37774185 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg duloxetine (GD)
Number of subjects: 60
Study 37774185 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline infusion (GC)
Number of subjects: 60
Study 37774188 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine infusion (LDKI) at 0.1 mg/kg/h
Number of subjects: 318
Study 37774508 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg every 4 weeks for three administrations) following long-course radiotherapy (RT) plus concomitant capecitabine (5040 cGy RT in 25-28 fractions over 5 weeks and capecitabine administered at 825 mg/m2)
Number of subjects: 60
Study 37774508 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 60
Study 37774646 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure treatment to goal < 120 mm Hg
Number of subjects: 610
Study 37774646 — intervention group
Group type: COMPARATOR
Intervention: Standard systolic blood pressure treatment to goal < 140 mm Hg
Number of subjects: 610
Study 37774646 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCB) exposure
Number of subjects: 610
Study 37774697 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP-X
Number of subjects: 128
Study 37774697 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 128
Study 37774729 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose inactivated poliovirus vaccine (IPV)
Number of subjects: 502
Study 37774842 — intervention group
Group type: EXPERIMENTAL
Intervention: Later stages of change toward meat reduction
Number of subjects: 25143
Study 37774842 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiated meat reduction
Number of subjects: 25143
Study 37774841 — intervention group
Group type: EXPERIMENTAL
Intervention: Deuterated water consumption for 10 days before surgery
Number of subjects: 49
Study 37774979 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week personalised activity plan
Number of subjects: 0
Study 37775187 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand-alone iCBT
Number of subjects: 279
Study 37775187 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided iCBT
Number of subjects: 279
Study 37775187 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 279
Study 37775282 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed financial incentives plus enhanced usual care
Number of subjects: 0
Study 37775282 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome-based financial incentives plus enhanced usual care
Number of subjects: 0
Study 37775282 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care alone
Number of subjects: 0
Study 37775290 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular renal denervation (RDN)
Number of subjects: 80
Study 37775290 — intervention group
Group type: COMPARATOR
Intervention: Classic renal arteriography and sham RDN
Number of subjects: 80
Study 37775297 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate oral semaglutide therapy
Number of subjects: 0
Study 37775297 — intervention group
Group type: COMPARATOR
Intervention: 2-year delay in oral semaglutide therapy
Number of subjects: 0
Study 37775472 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-IREAD-assisted group
Number of subjects: 290
Study 37775472 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 290
Study 37775521 — intervention group
Group type: EXPERIMENTAL
Intervention: PHH-1V vaccine formulations 10 µg
Number of subjects: 30
Study 37775521 — intervention group
Group type: EXPERIMENTAL
Intervention: PHH-1V vaccine formulations 20 µg
Number of subjects: 30
Study 37775521 — intervention group
Group type: EXPERIMENTAL
Intervention: PHH-1V vaccine formulations 40 µg
Number of subjects: 30
Study 37775521 — intervention group
Group type: COMPARATOR
Intervention: BNT162b2 (control)
Number of subjects: 30
Study 37775521 — intervention group
Group type: EXPERIMENTAL
Intervention: PHH-1V
Number of subjects: 30
Study 37775584 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel containing green tea extract and hyaluronic acid applied 3 times a day for 7 days
Number of subjects: 42
Study 37775584 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel applied 3 times a day for 7 days
Number of subjects: 42